Exelixis | EXEL - Net Income

Stock Price
42.36
Daily Change
-0.23 -0.54%
Monthly
-0.09%
Yearly
26.26%
Q1 Forecast
40.09

Exelixis reported $193.58M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.53B 83M Sep/2025
Bayer EUR -963M 764M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Eisai JPY 10.16B 4.32B Sep/2025
Eli Lilly USD 5.58B 78M Sep/2025
Exelixis USD 193.58M 8.73M Sep/2025
Genmab DKK 336M 141M Jun/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Takeda JPY 103.64B 115.44B Dec/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Xencor USD -6.03M 24.8M Sep/2025